$1.25
Live
1.6%
Downside
Day's Volatility :6.09%
Upside
4.57%
4.0%
Downside
52 Weeks Volatility :49.12%
Upside
47.0%
Period | Cumberland Pharmaceuticals Inc | Index (Russel 2000) |
---|---|---|
3 Months | -15.54% | 0.0% |
6 Months | -22.84% | 0.0% |
1 Year | -37.81% | 0.0% |
3 Years | -53.18% | -23.0% |
Market Capitalization | 18.0M |
Book Value | $1.87 |
Earnings Per Share (EPS) | -0.72 |
PEG Ratio | 0.0 |
Wall Street Target Price | 8.5 |
Profit Margin | -27.46% |
Operating Margin TTM | -10.42% |
Return On Assets TTM | -5.66% |
Return On Equity TTM | -32.99% |
Revenue TTM | 37.8M |
Revenue Per Share TTM | 2.67 |
Quarterly Revenue Growth YOY | -9.6% |
Gross Profit TTM | 32.9M |
EBITDA | -2.8M |
Diluted Eps TTM | -0.72 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 580.0%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 40.7M | ↓ 0.99% |
Net Income | -7.0M | ↓ 12.73% |
Net Profit Margin | -17.09% | ↑ 2.3% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 34.4M | ↓ 15.59% |
Net Income | -9.2M | ↑ 32.29% |
Net Profit Margin | -26.79% | ↓ 9.7% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 37.4M | ↑ 8.88% |
Net Income | -6.6M | ↓ 28.07% |
Net Profit Margin | -17.7% | ↑ 9.09% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 36.0M | ↓ 3.89% |
Net Income | -5.6M | ↓ 15.53% |
Net Profit Margin | -15.55% | ↑ 2.15% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 42.0M | ↑ 16.75% |
Net Income | -5.7M | ↑ 0.95% |
Net Profit Margin | -13.45% | ↑ 2.1% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 39.6M | ↓ 5.85% |
Net Income | -6.3M | ↑ 11.14% |
Net Profit Margin | -15.88% | ↓ 2.43% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.2M | ↑ 1.11% |
Net Income | 192.2K | ↓ 107.81% |
Net Profit Margin | 2.08% | ↑ 29.04% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.9M | ↑ 18.04% |
Net Income | 872.2K | ↑ 353.84% |
Net Profit Margin | 8.01% | ↑ 5.93% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.1M | ↓ 7.37% |
Net Income | -1.0M | ↓ 220.3% |
Net Profit Margin | -10.4% | ↓ 18.41% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.4M | ↓ 7.27% |
Net Income | -6.3M | ↑ 499.55% |
Net Profit Margin | -67.26% | ↓ 56.86% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 8.5M | ↓ 9.15% |
Net Income | -1.9M | ↓ 69.06% |
Net Profit Margin | -22.9% | ↑ 44.36% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 9.8M | ↑ 15.9% |
Net Income | -1.1M | ↓ 44.22% |
Net Profit Margin | -11.02% | ↑ 11.88% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 112.7M | ↑ 20.87% |
Total Liabilities | 57.1M | ↑ 94.89% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 104.5M | ↓ 7.23% |
Total Liabilities | 53.5M | ↓ 6.41% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 96.5M | ↓ 7.73% |
Total Liabilities | 49.6M | ↓ 7.25% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 84.5M | ↓ 12.44% |
Total Liabilities | 41.9M | ↓ 15.59% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 92.9M | ↑ 10.02% |
Total Liabilities | 57.0M | ↑ 36.06% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 81.8M | ↓ 12.0% |
Total Liabilities | 52.5M | ↓ 7.79% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 89.5M | ↓ 3.72% |
Total Liabilities | 53.4M | ↓ 6.2% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 89.4M | ↓ 0.1% |
Total Liabilities | 52.5M | ↓ 1.65% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 87.8M | ↓ 1.82% |
Total Liabilities | 52.1M | ↓ 0.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 81.8M | ↓ 6.81% |
Total Liabilities | 52.5M | ↑ 0.81% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 81.5M | ↓ 0.33% |
Total Liabilities | 54.3M | ↑ 3.43% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 78.5M | ↓ 3.67% |
Total Liabilities | 52.5M | ↓ 3.37% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.1M | ↓ 658.12% |
Investing Cash Flow | -27.7M | ↓ 391.45% |
Financing Cash Flow | 7.1M | ↑ 266.5% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.1M | ↓ 1.81% |
Investing Cash Flow | 2.3M | ↓ 108.29% |
Financing Cash Flow | -5.1M | ↓ 171.17% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.4M | ↑ 77.17% |
Investing Cash Flow | -1.8M | ↓ 176.5% |
Financing Cash Flow | -7.1M | ↑ 40.07% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 6.3M | ↑ 17.13% |
Investing Cash Flow | -501.9K | ↓ 71.45% |
Financing Cash Flow | -3.6M | ↓ 50.06% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.5M | ↑ 33.28% |
Investing Cash Flow | -13.7M | ↑ 2624.58% |
Financing Cash Flow | -2.1M | ↓ 41.98% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.4M | ↓ 149.87% |
Investing Cash Flow | -96.8K | ↓ 84.89% |
Financing Cash Flow | -1.8M | ↓ 36.02% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 5.2M | ↓ 469.15% |
Investing Cash Flow | -96.8K | ↑ 0.0% |
Financing Cash Flow | -3.3M | ↑ 84.11% |
Sell
Neutral
Buy
Cumberland Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Cumberland Pharmaceuticals Inc | 0.81% | -22.84% | -37.81% | -53.18% | -77.27% |
Neurocrine Biosciences Inc. | 0.22% | -11.71% | 9.36% | 13.47% | 21.32% |
Haleon Plc Spon Ads | -5.08% | 20.69% | 22.01% | 36.17% | 36.17% |
Zoetis Inc. | -0.16% | 32.8% | 16.08% | -7.35% | 52.85% |
Viatris Inc. | 2.53% | 4.53% | 31.84% | -16.06% | -28.03% |
Catalent, Inc. | 0.9% | 7.56% | 42.8% | -54.43% | 23.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Cumberland Pharmaceuticals Inc | NA | NA | 0.0 | 0.0 | -0.33 | -0.06 | NA | 1.87 |
Neurocrine Biosciences Inc. | 35.55 | 35.55 | 0.27 | 4.54 | 0.16 | 0.12 | NA | 24.87 |
Haleon Plc Spon Ads | 32.52 | 32.52 | 1.5 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 37.9 | 37.9 | 2.64 | 5.83 | 0.49 | 0.14 | 0.01 | 10.94 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.67 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 3.02 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Cumberland Pharmaceuticals Inc | Sell | $18.0M | -77.27% | NA | -27.46% |
Neurocrine Biosciences Inc. | Buy | $11.9B | 21.32% | 35.55 | 16.0% |
Haleon Plc Spon Ads | Buy | $45.6B | 36.17% | 32.52 | 9.66% |
Zoetis Inc. | Buy | $87.6B | 52.85% | 37.9 | 26.29% |
Viatris Inc. | Hold | $14.0B | -28.03% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $10.9B | 23.98% | 211.02 | -23.81% |
Insights on Cumberland Pharmaceuticals Inc
Revenue is up for the last 2 quarters, 8.49M → 9.84M (in $), with an average increase of 13.7% per quarter
Netprofit is up for the last 3 quarters, -6.29M → -1.08M (in $), with an average increase of 151.3% per quarter
In the last 1 year, Catalent, Inc. has given 43.0% return, outperforming this stock by 84.3%
Renaissance Technologies Corp
Vanguard Group Inc
Dimensional Fund Advisors, Inc.
Bridgeway Capital Management, LLC
BlackRock Inc
Geode Capital Management, LLC
cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.
Organization | Cumberland Pharmaceuticals Inc |
Employees | 91 |
CEO | Mr. A. J. Kazimi MBA |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$1.25
+0.0%
Invesco Bulletshares 2025 Hi
$1.25
+0.0%
Schwab International Dividend Equity Etf
$1.25
+0.0%
Blockchain Coinvestors Acquisition Corp.
$1.25
+0.0%
Allgiant Travel Company
$1.25
+0.0%
Rogers Corp
$1.25
+0.0%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$1.25
+0.0%
Iheartmedia
$1.25
+0.0%
Lightpath Technologies Inc
$1.25
+0.0%